SS
SPRO icon

SBI Securities’s Spero Therapeutics SPRO Stock Holding History

SBI Securities’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29 Buy
13
+4
+44% +$10 ﹤0.01% 3779
2026
Q1 		$21 Hold
9
– – ﹤0.01% 3758
2025
Q4 		$21 Sell
9
-1
-10% -$2 ﹤0.01% 3770
2025
Q3 		$19 Sell
10
-52
-84% -$114 ﹤0.01% 3930
2025
Q2 		$180 Buy
62
+2
+3% +$3 ﹤0.01% 3351
2025
Q1 		$43 Sell
60
-153
-72% -$129 ﹤0.01% 3688
2024
Q4 		$219 Buy
+213
New +$253 ﹤0.01% 3205

Other funds holding SPRO

GP
GSK plc London $602M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

SBI Securities's SPRO Position: Q2 2026 in Review

SBI Securities increased its Spero Therapeutics (SPRO) stake by 44% in Q2 2026, buying an estimated $10 and bringing the position to 13 shares worth $29. The position accounts for ﹤0.01% of the portfolio, ranked #3779.

SBI Securities first reported a position in SPRO in Q4 2024 and has held it in 7 quarters since. The position peaked at $219 in Q4 2024. 60 funds tracked by Wall St. Rank hold SPRO as of Q2 2026.

  • SBI Securities held 13 shares of Spero Therapeutics worth $29 as of Q2 2026.
  • SBI Securities bought 4 Spero Therapeutics shares in Q2 2026, an estimated $10.
  • Spero Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3779 holding.
  • SBI Securities first reported a position in Spero Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Spero Therapeutics position peaked at $219 in Q4 2024.
  • 60 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.